Kyowa Kirin (4151) Collaboration summary
Event summary combining transcript, slides, and related documents.
Collaboration summary
13 Jun, 2025Opening remarks and agenda
Agenda included the announcement of a global strategic collaboration with Kura Oncology to develop and commercialize ziftomenib.
Objectives of the partnership
Strengthen the pipeline in intractable hematological diseases and rare diseases through a license agreement for ziftomenib.
Maximize value and accelerate delivery of innovative therapies to patients globally.
Partner introductions and roles
Key executives involved: Chief Strategy Officer Yasuo Fujii, Chief Medical Officer Takeyoshi Yamashita, Head of Finance Motohiko Kawaguchi, and Chief International Business Officer Abdul Mullick.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Kyowa Kirin
- Double-digit revenue and profit growth driven by global product demand and tech-licensing.4151
Q2 2026 - Revenue and profit soared on global growth, tech-licensing, and raised profit guidance.4151Q1 2026
- Record FY2025 revenue and profit, with FY2026 guided for higher sales but lower core margin.4151Q4 2025
- Kyowa Kirin takes full control of rocatinlimab, aiming for 2026 regulatory submissions and strong market growth.4151Investor presentation
- Revenue and profit fell on restructuring and price cuts, but pipeline and cash flow remain robust.4151Q3 2025
- Revenue and profit fell, but overseas growth and pipeline progress remained strong.4151Q2 2025
- Driving innovation in rare disease therapies, talent, and sustainability for global impact.4151Sustainability Meeting Presentation
- Strong overseas growth and Orchard acquisition drove revenue and profit gains.4151Q3 2024
- Strong H1 growth led to upgraded full-year guidance, fueled by global expansion and FX gains.4151Q2 2024